See more : Inform P. Lykos Holdings S.A. (LYK.AT) Income Statement Analysis – Financial Results
Complete financial analysis of Rain Therapeutics Inc. (RAIN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rain Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bioqual, Inc. (BIOQ) Income Statement Analysis – Financial Results
- Global Communication Planning Co.,Ltd. (4073.T) Income Statement Analysis – Financial Results
- GCC, S.A.B. de C.V. (GCWOF) Income Statement Analysis – Financial Results
- Tres-Or Resources Ltd. (TRSFF) Income Statement Analysis – Financial Results
- Riley Gold Corp. (RLYGF) Income Statement Analysis – Financial Results
Rain Therapeutics Inc. (RAIN)
About Rain Therapeutics Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 61.40M | 40.77M | 15.37M | 7.29M |
| General & Administrative | 15.74M | 10.74M | 3.59M | 3.54M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.74M | 10.74M | 3.59M | 3.54M |
| Other Expenses | 0.00 | 1.00K | -2.02M | -251.00K |
| Operating Expenses | 77.14M | 51.51M | 18.96M | 10.83M |
| Cost & Expenses | 77.14M | 51.51M | 18.96M | 10.83M |
| Interest Income | 1.42M | 119.00K | 32.00K | 209.00K |
| Interest Expense | 0.00 | 0.00 | 135.00K | 32.00K |
| Depreciation & Amortization | 80.00K | 120.00K | -1.94M | -14.00K |
| EBITDA | -77.06M | -51.51M | -18.91M | -10.84M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -77.14M | -51.51M | -18.96M | -10.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | 120.00K | -2.13M | -74.00K |
| Income Before Tax | -75.72M | -51.39M | -21.08M | -10.90M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.00K | 2.00K | -1.89M | -219.00K |
| Net Income | -75.72M | -51.39M | -19.20M | -10.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.71 | -2.65 | -1.80 | -1.00 |
| EPS Diluted | -2.71 | -2.65 | -1.80 | -1.00 |
| Weighted Avg Shares Out | 27.99M | 19.41M | 10.66M | 10.66M |
| Weighted Avg Shares Out (Dil) | 27.99M | 19.41M | 10.66M | 10.66M |
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Rain Investors of a Lead Plaintiff Deadline of September 12, 2023
NEW YORK , July 24, 2023 /PRNewswire/ -- Attention Rain Oncology Inc. ("Rain") (NASDAQ: RAIN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between July 20, 2021...
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Rain Oncology Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ:RAIN) for violations of §§10(b)...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Rain Oncology Inc. (RAIN) Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Rain Oncology Inc. (“Rain” or the “Company”) (NASDAQ: RAIN) securities between July 20, 2021 and May 19,...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Rain Oncology Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ:RAIN) for violations of 10(b)...
RAIN SHAREHOLDER ALERT: Jakubowitz Law Reminds Rain Shareholders of a Lead Plaintiff Deadline of September 12, 2023
NEW YORK , July 21, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Rain Oncology Inc. (NASDAQ: RAIN). To receive updates on the lawsuit, fill out the form:...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Rain Oncology Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ:RAIN) for violations of §§10(b)...
RAIN LAWSUIT ALERT: Levi & Korsinsky Notifies Rain Oncology Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , July 20, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rain Oncology Inc. (RAIN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Rain Oncology Inc. (“Rain” or the “Company”) (NASDAQ: RAIN) investors concerning the Company's possible...
Calling All Rain Oncology Inc. (RAIN) Investors: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Class Action Lawsuit!
NEW YORK--(BUSINESS WIRE)---- $RAIN #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rain Oncology Inc. ("Rain" or “the Company”) (NASDAQ: RAIN) and certain of its officers....
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Rain Oncology Inc. (RAIN) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Rain Oncology Inc. (“Rain” or the “Company”) (NASDAQ: RAIN) investors concerning the Company's possible violations of federal securities laws. On May 22, 2023, Rain announced the...
Source: https://incomestatements.info
Category: Stock Reports